Clinical Trials Directory

Trials / Conditions / Immunoproliferative Disorders

Immunoproliferative Disorders

12 registered clinical trials studyying Immunoproliferative Disorders — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185
Kelonia Therapeutics, Inc.Phase 1
RecruitingA Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NCT06271252
OriCell Therapeutics Co., Ltd.Phase 1
WithdrawnA Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT05431179
Oncternal Therapeutics, IncPhase 3
UnknownNatural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
NCT04309084
Celularity IncorporatedPhase 1
Active Not RecruitingAnti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
NCT03696784
UNC Lineberger Comprehensive Cancer CenterPhase 1
Active Not RecruitingStudy of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
NCT03602157
UNC Lineberger Comprehensive Cancer CenterPhase 1
CompletedA Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymp
NCT03744676
Juno Therapeutics, a Subsidiary of CelgenePhase 2
UnknownChidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (
NCT03373019
Fudan UniversityPhase 2
Active Not RecruitingStudy of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
NCT02690545
UNC Lineberger Comprehensive Cancer CenterPhase 1 / Phase 2
Active Not RecruitingAdministration of T Lymphocytes for Prevention of Relapse of Lymphomas
NCT02663297
UNC Lineberger Comprehensive Cancer CenterPhase 1
Active Not RecruitingAdministration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refract
NCT03016377
UNC Lineberger Comprehensive Cancer CenterPhase 1 / Phase 2
No Longer AvailableCompassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Swit
NCT03594162
UNC Lineberger Comprehensive Cancer Center—